老年三阴性乳腺癌的临床病理特征及治疗

doi:0.3760/cma.j.issn.1673-422X.2013.12.013

摘要/Abstract

摘要： 老年三阴性乳腺癌(TNBC)具有独特的临床病理特征，除浸润性导管癌，也多见于腺癌、小叶癌，该类肿瘤体积大，分级多为Ⅲ级。老年TNBC患者辅助化疗疗效显著，但因常并发其他疾病，选择治疗方案时除考虑肿瘤分期外，还需注意患者重要器官功能及耐受能力。老年TNBC患者预后较差，给予合理治疗后，情况可明显改善。

关键词: 病理学, 临床, 老年人, 治疗, 乳腺肿瘤

Abstract: Triplenegative breast cancer (TNBC) in elderly patients presents distinctive clinicopathologic characteristics of large volume and histological grade Ⅲ, and it is seen most frequently in invasive ductal carcinoma, adenocarcinoma and lobular carcinoma. Elderly women with TNBC significantly benefit from adjuvant chemotherapy. But older women frequently have concurrent disease, so neoplasm staging, function of vital organs and tolerance of patient should be considered when treatment programs are selected．The prognosis of older TNBC patient is worse, but rational therapy can improve outcomes significantly.

Key words: Pathology, clinical, Aged, Therapy, Breast neoplasms

高静. 老年三阴性乳腺癌的临床病理特征及治疗[J]. 国际肿瘤学杂志, 2013, 40(12): 921-923.

GAO Jing. Clinicopathological features and therapies of elderly women with triplenegative breast cancer[J]. Journal of International Oncology, 2013, 40(12): 921-923.

参考文献

［1］ ReisFilho JS, Tutt AN. Triple negative tumours: a critical review. Histopatholog, 2008, 52(1): 108118. ［2］陈欣, 马睿锐, 周文斌, 等. 不同分子亚型老年性乳腺癌的临床病理特征与预后的相关性. 江苏医药, 2011, 37（13）: 1554. ［3］ Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph nodepositive breast cancer. JAMA, 2005, 293(9): 10731081. ［4］ Kang SP, Martel M, Harris LN. Triple negative breast cancer: current understangding of biology and treatment options. Curr Opin Obster Gynecol, 2008, 20(1): 4046. ［5］ Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)negative, and HER2negative invasive breast cancer, the socalled triplenegative phenotype: a populationbased study from the California cancer Registry. Cancer, 2007, 109(9): 17211728. ［6］ Yu KD, Li JJ, Di GH, et al. A straightforward but not piecewise relationship between age and lymph node status in Chinese breast cancer patients. PLoS One, 2010, 5(6): e11035. ［7］ Knigsberg R, Pfeiler G, Klement T, et al. Tumor characteristics and recurrence patterns in triplenegative breast cancer: a comparison between younger(＜65) and elderly (≥65) patients. Eur J Cancer, 2012, 48(16): 29622968. ［8］陆辉, 王水, 夏添松, 等. 240例乳腺癌组织中p53、cerbB2表达的临床分析. 江苏医药, 2007, 33(8): 790791. ［9］ Tischkowitz M, Brunet JS, Begin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer, 2007, 7: 134. ［10］ Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triplenegative/ basallike breast carcinomas. Breast Cancer Res, 2007, 9(5): R65. ［11］张萍，徐兵河，马飞，等. 老年三阴性乳腺癌临床病理特征及预后分析. 中国肿瘤临床与康复, 2010, 17(5): 390393. ［12］王琢，王丽娟，张颖超，等. 老年三阴型乳腺癌患者和青年患者临床生物学特征对比. 中国老年学杂志, 2013, 33(3): 694695. ［13］ Biganzoli L, Wildiers H, Oakman C, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol, 2012, 13: e148160. ［14］ Wildiers H, Kunkler I, Biganzoli L, et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol, 2007, 8(12): 11011115. ［15］ Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with earlystage breast cancer. N Engl J Med, 2009, 360（20）: 20552065. ［16］ Elkin EB, Hurria A, Mitra N, et al. Adjuvant chemotherapy and survival in older women with hormone receptornegative breast cancer: assessing outcome in a populationbased, observational cohort. J Clin Oncol, 2006, 24(18): 27572764. ［17］ Giordano SH, Duan Z, Kuo YF, et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol, 2006, 24（18）: 27502756. ［18］ Fargeot P, Bonneterre J, Roche H, et al. Diseasefree survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, nodepositive, elderly breast cancer patients: 6year followup results of the French adjuvant study group 08 trial. J Clin Oncol, 2004, 22（23）: 46224630. ［19］ Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol, 2007, 25（25）: 38083815. ［20］ Alessandra G， Maria PS， Paolo P， et al．HER2 status and eficacy of adjuvant anthracyclines in eady breast cancer: a pooled analysis of randomized trials． J Nad Cancer Inst， 2008， 100（1）: 1420. ［21］ Feher O, Vodvarka P, Jassem J, et al. Firstline gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase Ⅲ study. Ann Oncol, 2005, 16（6）: 899908. ［22］ Aapro M, BernardMarty C, Brain EG, et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol, 2011, 22（2）: 257267. ［23］ Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol, 2005, 23（10）: 21552161. ［24］ Blum JL, Kohles J, McKenna E, et al. Association of age and overall survival in capecitabinetreated patients with metastatic breast cancer in clinical trials. Breast Cancer Res Treat, 2011, 125(2): 431439. ［25］ Mikhail SE, Sun JF, Marshall JL. Safety of capecitabine: a review. Expert Opin Drug Saf, 2010, 9（5）: 831841. ［26］ Colleoni M, Orlando L, Sanna G, et al. Metronomic lowdose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol, 2006, 17（2）: 232238. ［27］ Salem DA, Gado NM, Abdelaziz NN, et al. Phase Ⅱ trial of metronomic chemotherapy as salvage therapy for patients with metastatic breast cancer. J Egypt Natl Canc Inst, 2008, 20（2）: 134140. ［28］ Biganzoli L, Di Vincenzo E, Jiang Z, et al. Firstline bevacizumabcontaining therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study. Ann Oncol, 2012, 23（1）: 111118. ［29］ Smith IE, Pierga JY, Biganzoli L, et al. Firstline bevacizumab plus taxanebased chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an openlabel study in 2,251 patients. Ann Oncol, 2011, 22（3）: 595602.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[4]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[5]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[6]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[7]	陈琦, 徐晨阳, 王寅, 雷大鹏. 高光谱成像在头颈部肿瘤诊疗中的应用现状[J]. 国际肿瘤学杂志, 2024, 51(5): 298-302.
[8]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[9]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[10]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[11]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[12]	王子豪, 王宇, 杨鑫, 何艺, 莫兴奎, 袁涛. 铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 239-244.
[13]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[14]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[15]	张丽丽, 谭茹, 房雪利, 杨宇, 桑铮, 李宝生. 乳腺导管原位癌影像学诊断、病理学升级及影像学技术进展[J]. 国际肿瘤学杂志, 2024, 51(3): 166-169.